FDMT News and Press, 4D Molecular Therapeutics Inc. From 02/05/24

2024-02-05 13:05:53 ET More on Mid-day movers $ stocks. Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade) Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky Peraso Inc. (PRSO) Q3 2023 Earnings Ca...

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is one of today's top gainers. The company's shares have moved -6.32% on the day to $17.49. 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops...

2024-02-05 10:00:03 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...

2024-02-05 08:31:42 ET Chenghe Acquisition  ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies  ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...

2024-02-05 05:15:09 ET Related stock stories: 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade) Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3...

2024-02-05 04:39:02 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular gets FDA rare pediatric disease status for CF drug Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics ...

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF injections in preceding 12 months) were randomized to high (3E10 vg/eye) or low (1E10 vg/eye) dose 4D-150 or aflibercep...

Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024 Conference on Saturday, February 3, 2024 during Session VI (3:30 to 5:...

2024-01-25 06:14:55 ET Summary Interim phase 1 data update using 4D-710 for the treatment of patients with Cystic Fibrosis expected in mid-2024. Program update on advancement of 4D-710 into pivotal study either alone or in combination with CFTR modular expected in Q1 of 2024. ...

2024-01-23 11:20:02 ET More on 4D Molecular Therapeutics Cantor starts 4D Molecular at overweight, says shares don't reflect progress Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics Historical earnings data for 4D Molecular Therapeutics Finan...